Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.

Saved in:
Bibliographic Details
Published in:JAMA Oncol
Main Authors: Kazandjian, Dickran, Korde, Neha, Mailankody, Sham, Hill, Elizabeth, Figg, William D., Roschewski, Mark, Landgren, Ola
Format: Artigo
Language:Inglês
Published: American Medical Association 2018
Subjects:
Research Letter
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440717/
https://ncbi.nlm.nih.gov/pubmed/30477009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5457
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items